Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation

Last updated: October 16, 2024
Sponsor: Insel Gruppe AG, University Hospital Bern
Overall Status: Active - Recruiting

Phase

4

Condition

Arrhythmia

Chest Pain

Atrial Fibrillation

Treatment

DOAC

Aspirin

P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel)

Clinical Study ID

NCT05955365
MATRIX-2
  • Ages > 18
  • All Genders

Study Summary

Patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation require treatment with different antithrombotic drugs. Oral anticoagulants are prescribed to reduce the risk of stroke associated with atrial fibrillation. Antiplatelet substances are prescribed after stent implantation to reduce the risk of adverse cardiac events such as myocardial infarction or stent thrombosis. Treatment with antithrombotic medications can cause bleeding complications, particularly when these substances are combined.

The currently recommended standard strategy consists of treatment with 3 antithrombotic medications for at least 1 week up to one month, followed by treatment with two of these medications for up to 6-12 months after stent implantation. Thereafter, patients usually receive long-term treatment with only one drug, an anticoagulant.

In the monotherapy group of this study, the investigators will investigate a strategy where only one antithrombotic drug will be used at a time. During the first month after stent implantation, the investigators will prescribe an antiplatelet medication, followed by an oral anticoagulant as monotherapy. This strategy might be associated with fewer bleeding complications, while protecting adequately against thrombotic events.

In this study the investigators would like to investigate whether treatment with a single antithrombotic drug ("monotherapy strategy") is associated with benefits compared to the currently recommended combination therapy of antithrombotic medications ("standard-of-care strategy").

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥18 years

  • Atrial fibrillation or flutter with an indication for oral anticoagulation usingdirect-acting oral anticoagulants (DOACs) for ≥12 months

  • Successful percutaneous coronary intervention in at least 1 lesion within theprevious 7 days with no remaining lesions intended for treatment.

  • Free from major adverse events post qualifying PCI, including new onset chest painsuspected to be of ischemic origin, acute or subacute stent thrombosis, new-onsetneurological signs or symptoms.

  • Written informed consent

Exclusion

Exclusion Criteria:

  • Planned staged percutaneous intervention procedure (Patients can be enrolled aftercomplete coronary revascularization with no remaining lesions intended fortreatment. Patients who have or develop indication to percutaneous valveintervention can undergo treatment more than 30 days after qualifying PCI.)

  • Cardioversion for treatment of atrial fibrillation within 1 month prior to inclusionor planned cardioversion

  • AF ablation procedure within 2 months prior to inclusion or planned AF ablationprocedure

  • Prior mechanical valvular prosthesis implantation

  • Deep vein thrombosis/pulmonary embolism, at least moderately severe mitral stenosisor other clinical conditions than atrial fibrillation requiring long-term oralanticoagulation

  • Stroke within 1 month prior to randomization

  • Hemodynamic instability (persistent systolic blood pressure below 90 mmHg,continuous infusions of catecholamines, clinical signs of hypoperfusion and/or useof percutaneous left ventricular assist devices)

  • Uncontrolled severe hypertension with a systolic blood pressure (BP) ≥180 mmHgand/or diastolic BP ≥120 mmHg

  • Severe renal impairment with estimated creatinine clearance (CrCL) <15 mL/min or ondialysis

  • Moderate or severe hepatic impairment (Child-Pugh Class B or C) or any hepaticdisease associated with coagulopathy

  • Any hypersensitivity or contraindications for direct oral anticoagulation or dualantiplatelet therapy with aspirin and a P2Y12 inhibitor

  • Any of the following abnormal local laboratory results prior to randomization:platelet count <50 x109/L or hemoglobin <8 g/dL

  • Known pregnancy or breast-feeding patients

  • Life expectancy <1 year due to other severe non-cardiac disease

  • Planned surgery including coronary artery bypass grafting within the next 6 months

Study Design

Total Participants: 3010
Treatment Group(s): 4
Primary Treatment: DOAC
Phase: 4
Study Start date:
December 18, 2023
Estimated Completion Date:
December 31, 2026

Study Description

Background:

The optimal antithrombotic treatment following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) requiring long-term oral anticoagulation remains a matter of debate. In particular, the appropriate intensity and duration of antithrombotic strategies to prevent ischemic events, while mitigating the risk of bleeding complications in this high bleeding risk population during the early peri-procedural period (within 30 days) and thereafter (from 30 days to 1 year) following drug-eluting stent implantation remains unclear.

Aim:

The investigators aim to assess the safety and efficacy of a P2Y12 inhibitor monotherapy regimen for 1 month followed by DOAC monotherapy long-term versus current standard of care consisting of triple antithrombotic therapy for up to one month (aspirin, P2Y12 inhibitor and DOAC) followed by dual antithrombotic therapy (P2Y12 inhibitor and DOAC) for 6 to 12 months and DOAC monotherapy thereafter, in AF patients undergoing PCI indicated for treatment with a DOAC after sirolimus-eluting Supraflex Cruz stent implantation and followed for a period of 12 months.

Methodology:

This investigator-initiated, multi-center, randomized, open-label, blinded evaluation, international clinical trial in 3010 AF patients with indication for long-term oral anticoagulation who have undergone successful PCI with Supraflex Cruz sirolimus-eluting biodegradable polymer cobalt chromium stent implantation. The study will be conducted at approximately 150 sites across Europe and Brazil. Patients will be randomized to the antithrombotic monotherapy (experimental antithrombotic strategy) or the standard of care strategy (control group) in a 1:1 ratio. Randomization is stratified by site, acute coronary syndrome (ACS) within the previous 6 months and CHA2DS2-VASc score ≥4. Patients randomized to the antithrombotic monotherapy treatment receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) and immediately discontinue aspirin and DOAC. After 1 month, the P2Y12 inhibitor will be stopped and treatment with a commercially available DOAC will be initiated for the duration of 11 months. Patients randomized to the standard of care strategy will initiate triple therapy for up to 1 month followed by dual anti-thrombotic therapy (consisting of P2Y12 inhibitor for a minimum of 6 and up to 12 months plus DOAC for at least 12 months).

Potential significance:

This is the first study investigation the impact of a short course of P2Y12 inhibitor monotherapy up to 1 month, while omitting clopidogrel non-responders, and temporarily omitting OAC, after stent implantation followed by OAC monotherapy in AF patients undergoing PCI. This sequential monotherapy treatment strategy has solid rational and carries potential to balance bleeding against cardiac and cerebral ischemic risks.

Connect with a study center

  • Hartcentrum Hasselt

    Hasselt, 3500
    Belgium

    Site Not Available

  • CHU Nîmes

    Nîmes, 30029
    France

    Site Not Available

  • Universitätsklinikum Frankfurt/Main

    Frankfurt am Main, 60590
    Germany

    Site Not Available

  • Klinikum Friedrichshafen

    Friedrichshafen, 88048
    Germany

    Site Not Available

  • Ospedale Ferrarotto

    Catania, Catania CT 95124
    Italy

    Site Not Available

  • IRCCS Humanitas

    Milano, Rozzano 20089
    Italy

    Site Not Available

  • UMC public

    Amsterdam, 1081
    Netherlands

    Site Not Available

  • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

    Poznań, 61-701
    Poland

    Site Not Available

  • Hospital Universitario Marques de Valdecilla

    Santander, 39008
    Spain

    Site Not Available

  • Cardiocentro Ticino Institute

    Lugano, Ticino 6900
    Switzerland

    Active - Recruiting

  • Universitätsspital Basel

    Basel, 4031
    Switzerland

    Active - Recruiting

  • Inselspital, Bern University Hospital, Department of Cardiology

    Bern, 3010
    Switzerland

    Active - Recruiting

  • Hôpitaux Universitaires de Genève

    Geneva, 1211
    Switzerland

    Active - Recruiting

  • Kantonsspital St. Gallen

    St.Gallen, 9007
    Switzerland

    Site Not Available

  • Stadtspital Triemli

    Zürich, 8063
    Switzerland

    Site Not Available

  • University Hospital Zürich

    Zürich, 8091
    Switzerland

    Active - Recruiting

  • Imperial College London

    London, SW7 2AZ
    United Kingdom

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.